Guggenheim raised the firm’s price target on Novo Nordisk (NVO) to DKK 798 from DKK 795 and keeps a Buy rating on the shares. The firm is updating its global biopharma coverage forecasts ahead of Q4 earnings following check-ins with investor relations teams and recent public commentary, the analyst tells investors in a preview for the group.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Insulin prices have dropped but some poor patients are paying more, NYT says
- Novo Nordisk Advances Share Repurchase Programme
- Drugmakers to push Trump to pause price negotiations, Bloomberg reports
- Eli Lilly (LLY) Expects Weight-Loss Pill Approval in 2026
- Novo Nordisk price target lowered to DKK 900 from DKK 1,000 at Deutsche Bank